PRIMARY STUDY
Endocannabinoid markers in autism spectrum disorder: A scoping review of human studies
Key Findings: The authors conclude that the ECS may be altered in humans with ASD.
Type of Study: Clinical Meta-analysis
Study Result: Inconclusive
Research Location(s): Canada
Year of Pub: 2021
Cannabinoids Studied: Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG)
Phytocannabinoid Source: Not Applicable
Citation: De Pol M and Kolla NJ. Endocannabinoid markers in autism spectrum disorder: A scoping review of human studies. Psychiatry Res. 2021; 306:114256. doi: 10.1016/j.psychres.2021.114256
Authors: De Pol M, Kolla NJ
